Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
Ultimately, the study will expand to other EU and non-EU countries, covering up to 80 clinical sites globally.
- Ultimately, the study will expand to other EU and non-EU countries, covering up to 80 clinical sites globally.
- RIVER-52 is a multicenter, open-label clinical trial designed to evaluate RVU120 in adult patients with r/r AML and HR-MDS, without alternative therapies.
- RIVER-52 represents the second of the four planned RVU120 Phase II clinical studies scheduled for launch in H1 2024.
- In addition to RIVER-52, Ryvu has already started patient treatment in the RIVER-81 study (evaluating RVU120 in combination with venetoclax for treating r/r AML patients).